Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADCT 
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ADCT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.2
1 Year Target Price $8.2
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 351.62% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 345.37M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 6 | Beta 1.93 | 52 Weeks Range 1.05 - 3.97 | Updated Date 08/29/2025 |
52 Weeks Range 1.05 - 3.97 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.39 | Actual -0.25 |
Profitability
Profit Margin -220% | Operating Margin (TTM) -164.85% |
Management Effectiveness
Return on Assets (TTM) -22.99% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 198336142 | Price to Sales(TTM) 4.47 |
Enterprise Value 198336142 | Price to Sales(TTM) 4.47 | ||
Enterprise Value to Revenue 2.57 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 112499000 | Shares Floating 92479003 |
Shares Outstanding 112499000 | Shares Floating 92479003 | ||
Percent Insiders 19.02 | Percent Institutions 64.57 |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA (ADCT) was founded in 2011 and is a commercial-stage biotechnology company focused on developing and commercializing antibody drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. It has evolved from a research-driven organization to one with approved products and a pipeline of clinical-stage candidates.
Core Business Areas
- Oncology Drug Development: ADCT focuses on the discovery, development, and commercialization of ADCs for cancer treatment. Their primary focus is hematological malignancies, but they also have programs targeting solid tumors.
Leadership and Structure
Dr. Ameet Mallik is the CEO. The company has a structured executive team and board of directors responsible for overseeing operations, strategy, and governance.
Top Products and Market Share
Key Offerings
- Zynlonta (loncastuximab tesirine-lpyl): Zynlonta is an ADC approved for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Revenue from Zynlonta in 2023 was approximately $77.9 million. Competitors include other therapies for r/r DLBCL, such as CAR-T cell therapies (e.g., Yescarta, Kymriah), and other chemotherapies.
Market Dynamics
Industry Overview
The oncology market is large and competitive, with increasing demand for targeted therapies like ADCs. The ADC market is rapidly growing with technological advancements and increasing regulatory approvals.
Positioning
ADCT is positioned as a key player in the ADC space, with an approved product and a pipeline of promising candidates. Their competitive advantage lies in their proprietary ADC technology platform.
Total Addressable Market (TAM)
The global ADC market is projected to reach tens of billions of USD. ADC Therapeutics is focusing on specific segments like relapsed/refractory DLBCL, which represents a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Approved ADC product (Zynlonta)
- Proprietary ADC technology platform
- Experienced management team
- Strong pipeline of clinical-stage candidates
Weaknesses
- Reliance on a single approved product
- High research and development costs
- Competition from larger pharmaceutical companies
- Need for additional funding
Opportunities
- Expansion of Zynlonta into earlier lines of therapy
- Development of new ADC candidates
- Partnerships with other pharmaceutical companies
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other ADC therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- GILD
- VRX
- TMO
- BMY
Competitive Landscape
ADCT's advantages include its proprietary ADC technology. Disadvantages include its smaller size and reliance on a single product compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced revenue growth driven by Zynlonta sales.
Future Projections: Analyst projections suggest continued revenue growth driven by expanded Zynlonta sales and potential approval of new products. Projections vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Zynlonta and other ADC candidates, as well as strategic partnerships.
Summary
ADC Therapeutics is a biotech company with an approved ADC product, Zynlonta, which drives its revenue. While the company has a promising technology platform, it faces challenges including competition and the need for additional funding. Its growth depends on the successful expansion of Zynlonta and the development of new ADC candidates. Investors should monitor clinical trial results and regulatory decisions. With a single approved product it is in a weak position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.